For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Sodium valproate (NON childbearing potential) - Epilepsy
PAD Profile : Sodium valproate (NON childbearing potential) - Epilepsy
Traffic Light Status
Status 1 of 3.
- Crushable tablets
- Gastro-resistant tablets
- Modified release tablets
- Oral solution
- Tablets
Status 2 of 3.
- Capsules (slow release)
- Granules (slow release)
Status 3 of 3.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Brivaracetam
- Sodium valproate
- Cannabidiol
- Vigabatrin
- Cenobamate
- Primidone
- Tiagabine
Other Indications
Additional Documents
Committee Recommendations
The Prescribing Clinical Network (PCN) recommends sodium valproate (all brands and salts) for males or females who are NOT of childbearing potential for the treatment of epilepsy or bipolar disorder.
Sodium valproate for these indications and for this cohort of patients will be considered BLUE (with an information sheet) on the traffic light system.
The specialist will prescribe a minimum of 1 month of sodium valproate at initiation and transfer of care will be requested with the patient’s primary care prescriber, once the patient is stable.